PT - JOURNAL ARTICLE AU - Shivangi Harankhedkar AU - Gaurav Chatterjee AU - Sweta Rajpal AU - Afreen Khan AU - Tuhina Srivastava AU - Sumeet Mirgh AU - Anant Gokarn AU - Sachin Punatar AU - Nitin Shetty AU - Amit Joshi AU - Sudhir Nair AU - Vedang Murthy AU - Prashant Tembhare AU - Ashwini More AU - Sujeet Kamtalwar AU - Preeti Chavan AU - Vivek Bhat AU - Amar Patil AU - Sachin Dhumal AU - Prashant Bhat AU - Papagudi Subramanian AU - Rachana Tripathi AU - Shesheer Munipally AU - Sumeet Gujral AU - Navin Khattry AU - Sudeep Gupta AU - Nikhil Patkar TI - N Gene Target Failure (NGTF) for detection of Omicron: a way out for the ‘stealth’ too? AID - 10.1101/2022.01.28.22269801 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.28.22269801 4099 - http://medrxiv.org/content/early/2022/02/01/2022.01.28.22269801.short 4100 - http://medrxiv.org/content/early/2022/02/01/2022.01.28.22269801.full AB - S-gene target failure (SGTF) is neither specific nor accurate for identification of Omicron lineage of SARS-CoV-2. We observed N-gene target failure (NGTF) in 402 out of 412 SARS-CoV2 positive cases from December to mid-January 2022 using a commercially available assay. This phenomenon was not observed with more than 15,000 cases tested previously. We sequenced the genome of five samples with NGTF and compared these results with six cases where NGTF was not seen. We confirm that cases with NGTF were the Omicron lineage while cases with preserved N-gene amplification belonged to Delta lineage. We discovered that the ERS31-33 deletion (nucleotide 28362-28370del) overlaps with N gene probe used, explaining NGTF. As the ‘stealth’ Omicron variant also harbors ERS31-33 deletion, this approach will work for the detection of ‘stealth’ Omicron variant as well. We suggest that NGTF can be used as a low cost, rapid screening strategy for detection of Omicron.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This paper was approved by the Tata Memorial Centre- Institutional Ethics CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors